Table 3.
Treatment for COVID-19.
| All (n = 44) | IMV (n = 34) | HFNC (n = 10) | p | |
|---|---|---|---|---|
| Antiviral treatment | ||||
| Azithromycin | 42 (95.5) | 32 (94.1) | 10 (100) | 0.432 |
| Hidroxicloroquine | 44 (100) | 34 (100) | 10 (100) | - |
| Lopinavir/ritonavir | 31 (70.5) | 26 (76.5) | 5 (50) | 0.107 |
| Remdesivir | 3 (6.8) | 3 (8.8) | 0 (0) | 0.331 |
| Immunomodulatory treatment | ||||
| Baricitinib | 4 (9.1) | 2 (5.9) | 2 (20) | 0.172 |
| Corticosteroids | 35 (79.5) | 28 (82.4) | 7 (70) | 0.395 |
| Interferon β-1b | 27 (61.4) | 21 (61.8) | 6 (60) | 0.920 |
| Tocilizumab | 36 (81.8) | 29 (85.3) | 7 (70) | 0.432 |
| Vitamin C | 12 (27.3) | 10 (29.4) | 2 (20) | 0.557 |
Data expressed as number (%), unless otherwise specified. HFNC, high flow nasal cannula; IMV, invasive mechanical ventilation.